I am a
Home I AM A Search Login

Papers of the Week


Papers: 2 Feb 2019 - 8 Feb 2019


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2019 Feb 01


J Headache Pain


20


1

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.

Authors

Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Adams A M, Lipton RB, Blumenfeld AM
J Headache Pain. 2019 Feb 01; 20(1):12.
PMID: 30709333.

Abstract

OnabotulinumtoxinA is effective in preventing chronic migraine (CM); however, the benefit of onabotulinumtoxinA in patients with CM with daily headache is unknown because these patients are typically excluded from clinical trials. This subanalysis of the COMPEL Study assessed the efficacy and safety of onabotulinumtoxinA in people with CM with and without daily headache.